nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—Docetaxel—skin cancer	0.0742	0.104	CbGbCtD
Erlotinib—ORM1—Vismodegib—skin cancer	0.074	0.104	CbGbCtD
Erlotinib—NR1I2—Docetaxel—skin cancer	0.0675	0.0946	CbGbCtD
Erlotinib—ORM1—Vemurafenib—skin cancer	0.0585	0.082	CbGbCtD
Erlotinib—ABCG2—Vismodegib—skin cancer	0.0452	0.0633	CbGbCtD
Erlotinib—ABCG2—Vemurafenib—skin cancer	0.0357	0.05	CbGbCtD
Erlotinib—ALB—Vismodegib—skin cancer	0.0311	0.0436	CbGbCtD
Erlotinib—CYP1A2—Imiquimod—skin cancer	0.0269	0.0377	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—skin cancer	0.0258	0.0361	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—skin cancer	0.0253	0.0354	CbGbCtD
Erlotinib—ALB—Vemurafenib—skin cancer	0.0246	0.0345	CbGbCtD
Erlotinib—CYP2C8—Vismodegib—skin cancer	0.0241	0.0337	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—skin cancer	0.0237	0.0332	CbGbCtD
Erlotinib—ABCB1—Vismodegib—skin cancer	0.0163	0.0228	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—skin cancer	0.016	0.0225	CbGbCtD
Erlotinib—CYP1A2—Vemurafenib—skin cancer	0.0147	0.0206	CbGbCtD
Erlotinib—CYP3A4—Imiquimod—skin cancer	0.0141	0.0197	CbGbCtD
Erlotinib—CYP3A4—Temozolomide—skin cancer	0.0141	0.0197	CbGbCtD
Erlotinib—ABCG2—Docetaxel—skin cancer	0.0123	0.0172	CbGbCtD
Erlotinib—CYP2D6—Vemurafenib—skin cancer	0.0121	0.017	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—skin cancer	0.0113	0.0158	CbGbCtD
Erlotinib—ALB—Fluorouracil—skin cancer	0.0111	0.0155	CbGbCtD
Erlotinib—CYP3A4—Vismodegib—skin cancer	0.00976	0.0137	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—skin cancer	0.00856	0.012	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—skin cancer	0.00855	0.012	CbGbCtD
Erlotinib—CYP3A4—Vemurafenib—skin cancer	0.00772	0.0108	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—skin cancer	0.00679	0.00951	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—skin cancer	0.00662	0.00927	CbGbCtD
Erlotinib—ABCB1—Docetaxel—skin cancer	0.00442	0.00619	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—skin cancer	0.00265	0.00371	CbGbCtD
Erlotinib—MKNK1—hair follicle—skin cancer	0.00207	0.032	CbGeAlD
Erlotinib—TNK1—nipple—skin cancer	0.00201	0.0311	CbGeAlD
Erlotinib—PIP4K2C—nipple—skin cancer	0.00156	0.0241	CbGeAlD
Erlotinib—JAK3—connective tissue—skin cancer	0.00155	0.024	CbGeAlD
Erlotinib—ULK3—nipple—skin cancer	0.00149	0.023	CbGeAlD
Erlotinib—MKNK1—nipple—skin cancer	0.0014	0.0217	CbGeAlD
Erlotinib—HIPK4—female reproductive system—skin cancer	0.00138	0.0214	CbGeAlD
Erlotinib—LTK—female reproductive system—skin cancer	0.00137	0.0212	CbGeAlD
Erlotinib—SLK—nipple—skin cancer	0.00133	0.0205	CbGeAlD
Erlotinib—FLT3—connective tissue—skin cancer	0.00122	0.019	CbGeAlD
Erlotinib—AURKC—female reproductive system—skin cancer	0.00118	0.0183	CbGeAlD
Erlotinib—TNK1—mammalian vulva—skin cancer	0.00117	0.0182	CbGeAlD
Erlotinib—LTK—head—skin cancer	0.00114	0.0177	CbGeAlD
Erlotinib—NR1I2—head—skin cancer	0.00114	0.0177	CbGeAlD
Erlotinib—JAK3—lymphoid tissue—skin cancer	0.00113	0.0176	CbGeAlD
Erlotinib—JAK3—female reproductive system—skin cancer	0.00109	0.0169	CbGeAlD
Erlotinib—EPHA6—female reproductive system—skin cancer	0.00109	0.0169	CbGeAlD
Erlotinib—MAP2K5—nipple—skin cancer	0.00103	0.016	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—skin cancer	0.000994	0.0154	CbGeAlD
Erlotinib—CYP1B1—hair follicle—skin cancer	0.000992	0.0154	CbGeAlD
Erlotinib—AURKC—head—skin cancer	0.000987	0.0153	CbGeAlD
Erlotinib—CYP1A1—skin epidermis—skin cancer	0.000983	0.0152	CbGeAlD
Erlotinib—EGFR—mammalian vulva—skin cancer	0.000939	0.0145	CbGeAlD
Erlotinib—EPHA6—head—skin cancer	0.000914	0.0142	CbGeAlD
Erlotinib—JAK3—head—skin cancer	0.000914	0.0142	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—skin cancer	0.00091	0.0141	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—skin cancer	0.000895	0.0139	CbGeAlD
Erlotinib—ULK3—mammalian vulva—skin cancer	0.000869	0.0135	CbGeAlD
Erlotinib—FLT3—female reproductive system—skin cancer	0.000863	0.0134	CbGeAlD
Erlotinib—MAP3K19—head—skin cancer	0.000831	0.0129	CbGeAlD
Erlotinib—MKNK1—mammalian vulva—skin cancer	0.000818	0.0127	CbGeAlD
Erlotinib—LTK—lymph node—skin cancer	0.000801	0.0124	CbGeAlD
Erlotinib—ABL1—nipple—skin cancer	0.000795	0.0123	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—skin cancer	0.00078	0.0121	CbGeAlD
Erlotinib—SLK—mammalian vulva—skin cancer	0.000775	0.012	CbGeAlD
Erlotinib—ULK3—female reproductive system—skin cancer	0.000744	0.0115	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—skin cancer	0.000726	0.0112	CbGeAlD
Erlotinib—MKNK1—female reproductive system—skin cancer	0.000701	0.0108	CbGeAlD
Erlotinib—AURKC—lymph node—skin cancer	0.000691	0.0107	CbGeAlD
Erlotinib—STK10—mammalian vulva—skin cancer	0.000674	0.0104	CbGeAlD
Erlotinib—PIP4K2C—head—skin cancer	0.000651	0.0101	CbGeAlD
Erlotinib—JAK3—lymph node—skin cancer	0.00064	0.00991	CbGeAlD
Erlotinib—ULK3—head—skin cancer	0.000622	0.00963	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—skin cancer	0.000602	0.00932	CbGeAlD
Erlotinib—STK10—lymphoid tissue—skin cancer	0.000598	0.00926	CbGeAlD
Erlotinib—TNK1—lymph node—skin cancer	0.000588	0.0091	CbGeAlD
Erlotinib—MKNK1—head—skin cancer	0.000585	0.00906	CbGeAlD
Erlotinib—STK10—female reproductive system—skin cancer	0.000577	0.00893	CbGeAlD
Erlotinib—ABL1—connective tissue—skin cancer	0.000564	0.00873	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—skin cancer	0.000515	0.00798	CbGeAlD
Erlotinib—ABL1—skin of body—skin cancer	0.000509	0.00788	CbGeAlD
Erlotinib—FLT3—lymph node—skin cancer	0.000505	0.00782	CbGeAlD
Erlotinib—CYP1A2—nipple—skin cancer	0.000482	0.00747	CbGeAlD
Erlotinib—ABL2—lymph node—skin cancer	0.000482	0.00746	CbGeAlD
Erlotinib—STK10—head—skin cancer	0.000482	0.00746	CbGeAlD
Erlotinib—CYP1B1—connective tissue—skin cancer	0.000477	0.00739	CbGeAlD
Erlotinib—CYP1A1—nipple—skin cancer	0.000476	0.00737	CbGeAlD
Erlotinib—EGFR—lymph node—skin cancer	0.00047	0.00729	CbGeAlD
Erlotinib—ABL1—mammalian vulva—skin cancer	0.000464	0.00719	CbGeAlD
Erlotinib—PIP4K2C—lymph node—skin cancer	0.000456	0.00706	CbGeAlD
Erlotinib—ULK3—lymph node—skin cancer	0.000435	0.00674	CbGeAlD
Erlotinib—CYP1B1—skin of body—skin cancer	0.000431	0.00667	CbGeAlD
Erlotinib—MAP2K5—head—skin cancer	0.00043	0.00667	CbGeAlD
Erlotinib—ORM1—female reproductive system—skin cancer	0.000418	0.00648	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—skin cancer	0.000412	0.00638	CbGeAlD
Erlotinib—MKNK1—lymph node—skin cancer	0.00041	0.00635	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—skin cancer	0.000401	0.00621	CbGeAlD
Erlotinib—ABL1—female reproductive system—skin cancer	0.000397	0.00616	CbGeAlD
Erlotinib—SLK—lymph node—skin cancer	0.000388	0.00601	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—skin cancer	0.000349	0.0054	CbGeAlD
Erlotinib—ABCB1—blood vessel—skin cancer	0.000342	0.00529	CbGeAlD
Erlotinib—STK10—lymph node—skin cancer	0.000337	0.00523	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—skin cancer	0.000337	0.00521	CbGeAlD
Erlotinib—SLCO2B1—head—skin cancer	0.000335	0.00519	CbGeAlD
Erlotinib—ABL1—head—skin cancer	0.000332	0.00514	CbGeAlD
Erlotinib—CYP1A1—epithelium—skin cancer	0.00032	0.00496	CbGeAlD
Erlotinib—CYP1A1—skin of body—skin cancer	0.000305	0.00472	CbGeAlD
Erlotinib—MAP2K5—lymph node—skin cancer	0.000301	0.00467	CbGeAlD
Erlotinib—Oedema—Imiquimod—skin cancer	0.000299	0.00174	CcSEcCtD
Erlotinib—Haemorrhage—Bleomycin—skin cancer	0.000299	0.00174	CcSEcCtD
Erlotinib—Infection—Imiquimod—skin cancer	0.000297	0.00173	CcSEcCtD
Erlotinib—Neutropenia—Temozolomide—skin cancer	0.000295	0.00172	CcSEcCtD
Erlotinib—Shock—Imiquimod—skin cancer	0.000294	0.00171	CcSEcCtD
Erlotinib—Nervous system disorder—Imiquimod—skin cancer	0.000293	0.00171	CcSEcCtD
Erlotinib—ABCG2—mammalian vulva—skin cancer	0.000293	0.00453	CbGeAlD
Erlotinib—Skin disorder—Imiquimod—skin cancer	0.000291	0.00169	CcSEcCtD
Erlotinib—Dysphagia—Fluorouracil—skin cancer	0.000291	0.00169	CcSEcCtD
Erlotinib—Sepsis—Docetaxel—skin cancer	0.00029	0.00169	CcSEcCtD
Erlotinib—Weight decreased—Temozolomide—skin cancer	0.000285	0.00166	CcSEcCtD
Erlotinib—Anorexia—Imiquimod—skin cancer	0.000285	0.00166	CcSEcCtD
Erlotinib—Pneumonia—Temozolomide—skin cancer	0.000283	0.00165	CcSEcCtD
Erlotinib—CYP1B1—head—skin cancer	0.000281	0.00435	CbGeAlD
Erlotinib—Infestation—Temozolomide—skin cancer	0.000281	0.00164	CcSEcCtD
Erlotinib—Infestation NOS—Temozolomide—skin cancer	0.000281	0.00164	CcSEcCtD
Erlotinib—Depression—Temozolomide—skin cancer	0.00028	0.00163	CcSEcCtD
Erlotinib—Hepatitis—Dactinomycin—skin cancer	0.000279	0.00162	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000279	0.00162	CcSEcCtD
Erlotinib—CYP1A1—mammalian vulva—skin cancer	0.000278	0.0043	CbGeAlD
Erlotinib—Body temperature increased—Vemurafenib—skin cancer	0.000277	0.00161	CcSEcCtD
Erlotinib—Neuropathy peripheral—Temozolomide—skin cancer	0.000276	0.0016	CcSEcCtD
Erlotinib—Stomatitis—Temozolomide—skin cancer	0.000274	0.0016	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000273	0.00159	CcSEcCtD
Erlotinib—Insomnia—Imiquimod—skin cancer	0.000271	0.00158	CcSEcCtD
Erlotinib—Hepatic failure—Docetaxel—skin cancer	0.00027	0.00157	CcSEcCtD
Erlotinib—Chills—Bleomycin—skin cancer	0.000268	0.00156	CcSEcCtD
Erlotinib—Dyspnoea—Imiquimod—skin cancer	0.000267	0.00155	CcSEcCtD
Erlotinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000266	0.00155	CcSEcCtD
Erlotinib—Alopecia—Bleomycin—skin cancer	0.000264	0.00154	CcSEcCtD
Erlotinib—Erythema multiforme—Dactinomycin—skin cancer	0.000264	0.00154	CcSEcCtD
Erlotinib—Dyspepsia—Imiquimod—skin cancer	0.000263	0.00153	CcSEcCtD
Erlotinib—Pneumonia—Fluorouracil—skin cancer	0.000261	0.00152	CcSEcCtD
Erlotinib—Erythema—Bleomycin—skin cancer	0.00026	0.00152	CcSEcCtD
Erlotinib—Decreased appetite—Imiquimod—skin cancer	0.00026	0.00151	CcSEcCtD
Erlotinib—Infestation—Fluorouracil—skin cancer	0.000259	0.00151	CcSEcCtD
Erlotinib—Infestation NOS—Fluorouracil—skin cancer	0.000259	0.00151	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000258	0.0015	CcSEcCtD
Erlotinib—Fatigue—Imiquimod—skin cancer	0.000258	0.0015	CcSEcCtD
Erlotinib—CYP2C8—female reproductive system—skin cancer	0.000258	0.00399	CbGeAlD
Erlotinib—Pain—Imiquimod—skin cancer	0.000256	0.00149	CcSEcCtD
Erlotinib—Acute coronary syndrome—Fluorouracil—skin cancer	0.000255	0.00149	CcSEcCtD
Erlotinib—Renal impairment—Docetaxel—skin cancer	0.000255	0.00148	CcSEcCtD
Erlotinib—Neuropathy peripheral—Fluorouracil—skin cancer	0.000254	0.00148	CcSEcCtD
Erlotinib—Myocardial infarction—Fluorouracil—skin cancer	0.000254	0.00148	CcSEcCtD
Erlotinib—Dermatitis bullous—Docetaxel—skin cancer	0.000254	0.00148	CcSEcCtD
Erlotinib—Haemoglobin—Temozolomide—skin cancer	0.000254	0.00148	CcSEcCtD
Erlotinib—Stomatitis—Fluorouracil—skin cancer	0.000253	0.00147	CcSEcCtD
Erlotinib—Haemorrhage—Temozolomide—skin cancer	0.000252	0.00147	CcSEcCtD
Erlotinib—Hepatitis—Temozolomide—skin cancer	0.000252	0.00147	CcSEcCtD
Erlotinib—Conjunctivitis—Fluorouracil—skin cancer	0.000252	0.00147	CcSEcCtD
Erlotinib—Asthenia—Vemurafenib—skin cancer	0.000252	0.00147	CcSEcCtD
Erlotinib—Chills—Dactinomycin—skin cancer	0.00025	0.00146	CcSEcCtD
Erlotinib—Urinary tract disorder—Temozolomide—skin cancer	0.000249	0.00145	CcSEcCtD
Erlotinib—Pruritus—Vemurafenib—skin cancer	0.000248	0.00145	CcSEcCtD
Erlotinib—Connective tissue disorder—Temozolomide—skin cancer	0.000248	0.00144	CcSEcCtD
Erlotinib—Urethral disorder—Temozolomide—skin cancer	0.000247	0.00144	CcSEcCtD
Erlotinib—Alopecia—Dactinomycin—skin cancer	0.000247	0.00144	CcSEcCtD
Erlotinib—Gastrointestinal pain—Imiquimod—skin cancer	0.000245	0.00142	CcSEcCtD
Erlotinib—ORM1—lymph node—skin cancer	0.000245	0.00379	CbGeAlD
Erlotinib—Epistaxis—Fluorouracil—skin cancer	0.000244	0.00142	CcSEcCtD
Erlotinib—Erythema—Dactinomycin—skin cancer	0.000243	0.00141	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000243	0.00141	CcSEcCtD
Erlotinib—Diarrhoea—Vemurafenib—skin cancer	0.00024	0.0014	CcSEcCtD
Erlotinib—Erythema multiforme—Temozolomide—skin cancer	0.000239	0.00139	CcSEcCtD
Erlotinib—CYP1A1—female reproductive system—skin cancer	0.000238	0.00368	CbGeAlD
Erlotinib—Abdominal pain—Imiquimod—skin cancer	0.000237	0.00138	CcSEcCtD
Erlotinib—Body temperature increased—Imiquimod—skin cancer	0.000237	0.00138	CcSEcCtD
Erlotinib—Eye disorder—Temozolomide—skin cancer	0.000236	0.00137	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—skin cancer	0.000235	0.00363	CbGeAlD
Erlotinib—Haemoglobin—Fluorouracil—skin cancer	0.000234	0.00136	CcSEcCtD
Erlotinib—Haemorrhage—Fluorouracil—skin cancer	0.000233	0.00135	CcSEcCtD
Erlotinib—ABL1—lymph node—skin cancer	0.000232	0.0036	CbGeAlD
Erlotinib—Dizziness—Vemurafenib—skin cancer	0.000232	0.00135	CcSEcCtD
Erlotinib—Mediastinal disorder—Temozolomide—skin cancer	0.000227	0.00132	CcSEcCtD
Erlotinib—Cough—Bleomycin—skin cancer	0.000227	0.00132	CcSEcCtD
Erlotinib—Chills—Temozolomide—skin cancer	0.000226	0.00132	CcSEcCtD
Erlotinib—Dehydration—Docetaxel—skin cancer	0.000226	0.00131	CcSEcCtD
Erlotinib—Vomiting—Vemurafenib—skin cancer	0.000223	0.0013	CcSEcCtD
Erlotinib—Alopecia—Temozolomide—skin cancer	0.000223	0.0013	CcSEcCtD
Erlotinib—Dry skin—Docetaxel—skin cancer	0.000222	0.00129	CcSEcCtD
Erlotinib—Chest pain—Bleomycin—skin cancer	0.000222	0.00129	CcSEcCtD
Erlotinib—Myalgia—Bleomycin—skin cancer	0.000222	0.00129	CcSEcCtD
Erlotinib—Rash—Vemurafenib—skin cancer	0.000221	0.00129	CcSEcCtD
Erlotinib—Mental disorder—Temozolomide—skin cancer	0.000221	0.00129	CcSEcCtD
Erlotinib—Dermatitis—Vemurafenib—skin cancer	0.000221	0.00129	CcSEcCtD
Erlotinib—Headache—Vemurafenib—skin cancer	0.00022	0.00128	CcSEcCtD
Erlotinib—Malnutrition—Temozolomide—skin cancer	0.00022	0.00128	CcSEcCtD
Erlotinib—Erythema—Temozolomide—skin cancer	0.00022	0.00128	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000219	0.00127	CcSEcCtD
Erlotinib—Asthenia—Imiquimod—skin cancer	0.000215	0.00125	CcSEcCtD
Erlotinib—ALB—lymph node—skin cancer	0.000215	0.00332	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000214	0.00125	CcSEcCtD
Erlotinib—Oedema—Bleomycin—skin cancer	0.000213	0.00124	CcSEcCtD
Erlotinib—Back pain—Temozolomide—skin cancer	0.000213	0.00124	CcSEcCtD
Erlotinib—Pruritus—Imiquimod—skin cancer	0.000212	0.00123	CcSEcCtD
Erlotinib—Infection—Bleomycin—skin cancer	0.000211	0.00123	CcSEcCtD
Erlotinib—Dysphagia—Docetaxel—skin cancer	0.00021	0.00122	CcSEcCtD
Erlotinib—Nausea—Vemurafenib—skin cancer	0.000208	0.00121	CcSEcCtD
Erlotinib—Thrombocytopenia—Bleomycin—skin cancer	0.000208	0.00121	CcSEcCtD
Erlotinib—Arrhythmia—Fluorouracil—skin cancer	0.000208	0.00121	CcSEcCtD
Erlotinib—Myalgia—Dactinomycin—skin cancer	0.000207	0.0012	CcSEcCtD
Erlotinib—Alopecia—Fluorouracil—skin cancer	0.000206	0.0012	CcSEcCtD
Erlotinib—Diarrhoea—Imiquimod—skin cancer	0.000205	0.00119	CcSEcCtD
Erlotinib—Anorexia—Bleomycin—skin cancer	0.000203	0.00118	CcSEcCtD
Erlotinib—Erythema—Fluorouracil—skin cancer	0.000202	0.00118	CcSEcCtD
Erlotinib—CYP1A1—head—skin cancer	0.000199	0.00308	CbGeAlD
Erlotinib—Oedema—Dactinomycin—skin cancer	0.000198	0.00115	CcSEcCtD
Erlotinib—Dizziness—Imiquimod—skin cancer	0.000198	0.00115	CcSEcCtD
Erlotinib—Infection—Dactinomycin—skin cancer	0.000197	0.00115	CcSEcCtD
Erlotinib—CYP1B1—lymph node—skin cancer	0.000197	0.00305	CbGeAlD
Erlotinib—Neutropenia—Docetaxel—skin cancer	0.000196	0.00114	CcSEcCtD
Erlotinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000194	0.00113	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000194	0.00113	CcSEcCtD
Erlotinib—Cough—Temozolomide—skin cancer	0.000192	0.00112	CcSEcCtD
Erlotinib—Vomiting—Imiquimod—skin cancer	0.00019	0.00111	CcSEcCtD
Erlotinib—Weight decreased—Docetaxel—skin cancer	0.00019	0.0011	CcSEcCtD
Erlotinib—Dyspnoea—Bleomycin—skin cancer	0.00019	0.0011	CcSEcCtD
Erlotinib—Anorexia—Dactinomycin—skin cancer	0.000189	0.0011	CcSEcCtD
Erlotinib—Rash—Imiquimod—skin cancer	0.000189	0.0011	CcSEcCtD
Erlotinib—Dermatitis—Imiquimod—skin cancer	0.000189	0.0011	CcSEcCtD
Erlotinib—Pneumonia—Docetaxel—skin cancer	0.000188	0.00109	CcSEcCtD
Erlotinib—Headache—Imiquimod—skin cancer	0.000187	0.00109	CcSEcCtD
Erlotinib—Myalgia—Temozolomide—skin cancer	0.000187	0.00109	CcSEcCtD
Erlotinib—Arthralgia—Temozolomide—skin cancer	0.000187	0.00109	CcSEcCtD
Erlotinib—Infestation NOS—Docetaxel—skin cancer	0.000187	0.00109	CcSEcCtD
Erlotinib—Infestation—Docetaxel—skin cancer	0.000187	0.00109	CcSEcCtD
Erlotinib—Anxiety—Temozolomide—skin cancer	0.000186	0.00109	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000186	0.00108	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000185	0.00108	CcSEcCtD
Erlotinib—Decreased appetite—Bleomycin—skin cancer	0.000185	0.00108	CcSEcCtD
Erlotinib—Acute coronary syndrome—Docetaxel—skin cancer	0.000184	0.00107	CcSEcCtD
Erlotinib—Renal failure—Docetaxel—skin cancer	0.000184	0.00107	CcSEcCtD
Erlotinib—Myocardial infarction—Docetaxel—skin cancer	0.000183	0.00107	CcSEcCtD
Erlotinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000183	0.00107	CcSEcCtD
Erlotinib—Stomatitis—Docetaxel—skin cancer	0.000182	0.00106	CcSEcCtD
Erlotinib—Pain—Bleomycin—skin cancer	0.000182	0.00106	CcSEcCtD
Erlotinib—Conjunctivitis—Docetaxel—skin cancer	0.000182	0.00106	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000181	0.00105	CcSEcCtD
Erlotinib—Oedema—Temozolomide—skin cancer	0.000179	0.00104	CcSEcCtD
Erlotinib—Infection—Temozolomide—skin cancer	0.000178	0.00104	CcSEcCtD
Erlotinib—Nausea—Imiquimod—skin cancer	0.000178	0.00103	CcSEcCtD
Erlotinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000177	0.00103	CcSEcCtD
Erlotinib—Epistaxis—Docetaxel—skin cancer	0.000176	0.00103	CcSEcCtD
Erlotinib—Nervous system disorder—Temozolomide—skin cancer	0.000176	0.00102	CcSEcCtD
Erlotinib—Thrombocytopenia—Temozolomide—skin cancer	0.000176	0.00102	CcSEcCtD
Erlotinib—CYP3A4—female reproductive system—skin cancer	0.000175	0.0027	CbGeAlD
Erlotinib—Skin disorder—Temozolomide—skin cancer	0.000174	0.00101	CcSEcCtD
Erlotinib—Chest pain—Fluorouracil—skin cancer	0.000172	0.001	CcSEcCtD
Erlotinib—Myalgia—Fluorouracil—skin cancer	0.000172	0.001	CcSEcCtD
Erlotinib—Decreased appetite—Dactinomycin—skin cancer	0.000172	0.001	CcSEcCtD
Erlotinib—CYP2D6—female reproductive system—skin cancer	0.000172	0.00266	CbGeAlD
Erlotinib—Fatigue—Dactinomycin—skin cancer	0.000171	0.000995	CcSEcCtD
Erlotinib—Anorexia—Temozolomide—skin cancer	0.000171	0.000995	CcSEcCtD
Erlotinib—Pain—Dactinomycin—skin cancer	0.00017	0.000987	CcSEcCtD
Erlotinib—Haemoglobin—Docetaxel—skin cancer	0.000169	0.000982	CcSEcCtD
Erlotinib—Body temperature increased—Bleomycin—skin cancer	0.000168	0.000978	CcSEcCtD
Erlotinib—Hepatitis—Docetaxel—skin cancer	0.000168	0.000977	CcSEcCtD
Erlotinib—Haemorrhage—Docetaxel—skin cancer	0.000168	0.000977	CcSEcCtD
Erlotinib—ABCB1—epithelium—skin cancer	0.000166	0.00258	CbGeAlD
Erlotinib—Urinary tract disorder—Docetaxel—skin cancer	0.000166	0.000965	CcSEcCtD
Erlotinib—Oedema—Fluorouracil—skin cancer	0.000165	0.000962	CcSEcCtD
Erlotinib—Connective tissue disorder—Docetaxel—skin cancer	0.000165	0.00096	CcSEcCtD
Erlotinib—Urethral disorder—Docetaxel—skin cancer	0.000165	0.000958	CcSEcCtD
Erlotinib—Infection—Fluorouracil—skin cancer	0.000164	0.000955	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000163	0.000951	CcSEcCtD
Erlotinib—Insomnia—Temozolomide—skin cancer	0.000162	0.000944	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000162	0.000944	CcSEcCtD
Erlotinib—Nervous system disorder—Fluorouracil—skin cancer	0.000162	0.000943	CcSEcCtD
Erlotinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000162	0.000942	CcSEcCtD
Erlotinib—Dyspnoea—Temozolomide—skin cancer	0.00016	0.000931	CcSEcCtD
Erlotinib—Erythema multiforme—Docetaxel—skin cancer	0.000159	0.000924	CcSEcCtD
Erlotinib—Dyspepsia—Temozolomide—skin cancer	0.000158	0.000919	CcSEcCtD
Erlotinib—Anorexia—Fluorouracil—skin cancer	0.000158	0.000917	CcSEcCtD
Erlotinib—Eye disorder—Docetaxel—skin cancer	0.000157	0.000913	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—skin cancer	0.000157	0.000912	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—skin cancer	0.000157	0.000912	CcSEcCtD
Erlotinib—Decreased appetite—Temozolomide—skin cancer	0.000156	0.000907	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.000155	0.000901	CcSEcCtD
Erlotinib—Fatigue—Temozolomide—skin cancer	0.000155	0.0009	CcSEcCtD
Erlotinib—Constipation—Temozolomide—skin cancer	0.000153	0.000893	CcSEcCtD
Erlotinib—Pain—Temozolomide—skin cancer	0.000153	0.000893	CcSEcCtD
Erlotinib—Asthenia—Bleomycin—skin cancer	0.000153	0.000888	CcSEcCtD
Erlotinib—Mediastinal disorder—Docetaxel—skin cancer	0.000151	0.000881	CcSEcCtD
Erlotinib—Chills—Docetaxel—skin cancer	0.000151	0.000877	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000151	0.000876	CcSEcCtD
Erlotinib—Pruritus—Bleomycin—skin cancer	0.00015	0.000875	CcSEcCtD
Erlotinib—Arrhythmia—Docetaxel—skin cancer	0.00015	0.000873	CcSEcCtD
Erlotinib—Insomnia—Fluorouracil—skin cancer	0.000149	0.00087	CcSEcCtD
Erlotinib—Alopecia—Docetaxel—skin cancer	0.000148	0.000863	CcSEcCtD
Erlotinib—Dyspnoea—Fluorouracil—skin cancer	0.000147	0.000857	CcSEcCtD
Erlotinib—Mental disorder—Docetaxel—skin cancer	0.000147	0.000856	CcSEcCtD
Erlotinib—Gastrointestinal pain—Temozolomide—skin cancer	0.000147	0.000854	CcSEcCtD
Erlotinib—ABCG2—lymph node—skin cancer	0.000147	0.00227	CbGeAlD
Erlotinib—Erythema—Docetaxel—skin cancer	0.000146	0.000851	CcSEcCtD
Erlotinib—Malnutrition—Docetaxel—skin cancer	0.000146	0.000851	CcSEcCtD
Erlotinib—Dyspepsia—Fluorouracil—skin cancer	0.000145	0.000847	CcSEcCtD
Erlotinib—ABCB1—mammalian vulva—skin cancer	0.000144	0.00224	CbGeAlD
Erlotinib—Decreased appetite—Fluorouracil—skin cancer	0.000144	0.000836	CcSEcCtD
Erlotinib—CYP2D6—head—skin cancer	0.000144	0.00222	CbGeAlD
Erlotinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000143	0.00083	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—skin cancer	0.000142	0.000828	CcSEcCtD
Erlotinib—Body temperature increased—Temozolomide—skin cancer	0.000142	0.000825	CcSEcCtD
Erlotinib—Abdominal pain—Temozolomide—skin cancer	0.000142	0.000825	CcSEcCtD
Erlotinib—Back pain—Docetaxel—skin cancer	0.000141	0.000823	CcSEcCtD
Erlotinib—Pain—Fluorouracil—skin cancer	0.000141	0.000822	CcSEcCtD
Erlotinib—CYP1A1—lymph node—skin cancer	0.000139	0.00216	CbGeAlD
Erlotinib—Diarrhoea—Dactinomycin—skin cancer	0.000136	0.00079	CcSEcCtD
Erlotinib—Vomiting—Bleomycin—skin cancer	0.000135	0.000787	CcSEcCtD
Erlotinib—Rash—Bleomycin—skin cancer	0.000134	0.00078	CcSEcCtD
Erlotinib—Dermatitis—Bleomycin—skin cancer	0.000134	0.00078	CcSEcCtD
Erlotinib—Syncope—Docetaxel—skin cancer	0.000131	0.000763	CcSEcCtD
Erlotinib—Body temperature increased—Fluorouracil—skin cancer	0.000131	0.00076	CcSEcCtD
Erlotinib—Asthenia—Temozolomide—skin cancer	0.000129	0.000749	CcSEcCtD
Erlotinib—Loss of consciousness—Docetaxel—skin cancer	0.000128	0.000748	CcSEcCtD
Erlotinib—ABCB1—lymphoid tissue—skin cancer	0.000128	0.00198	CbGeAlD
Erlotinib—Cough—Docetaxel—skin cancer	0.000128	0.000742	CcSEcCtD
Erlotinib—Pruritus—Temozolomide—skin cancer	0.000127	0.000739	CcSEcCtD
Erlotinib—Nausea—Bleomycin—skin cancer	0.000126	0.000735	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—skin cancer	0.000126	0.000734	CcSEcCtD
Erlotinib—Rash—Dactinomycin—skin cancer	0.000125	0.000728	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—skin cancer	0.000124	0.000724	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—skin cancer	0.000124	0.000724	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—skin cancer	0.000124	0.000724	CcSEcCtD
Erlotinib—ABCB1—female reproductive system—skin cancer	0.000124	0.00191	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000124	0.000719	CcSEcCtD
Erlotinib—Diarrhoea—Temozolomide—skin cancer	0.000123	0.000714	CcSEcCtD
Erlotinib—Oedema—Docetaxel—skin cancer	0.000119	0.000694	CcSEcCtD
Erlotinib—Dizziness—Temozolomide—skin cancer	0.000119	0.00069	CcSEcCtD
Erlotinib—Infection—Docetaxel—skin cancer	0.000118	0.00069	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—skin cancer	0.000118	0.000686	CcSEcCtD
Erlotinib—Shock—Docetaxel—skin cancer	0.000117	0.000683	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—skin cancer	0.000117	0.000681	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—skin cancer	0.000117	0.00068	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—skin cancer	0.000117	0.00068	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—skin cancer	0.000116	0.000674	CcSEcCtD
Erlotinib—Vomiting—Temozolomide—skin cancer	0.000114	0.000664	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—skin cancer	0.000114	0.000662	CcSEcCtD
Erlotinib—Rash—Temozolomide—skin cancer	0.000113	0.000658	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—skin cancer	0.000113	0.000658	CcSEcCtD
Erlotinib—Dermatitis—Temozolomide—skin cancer	0.000113	0.000658	CcSEcCtD
Erlotinib—Headache—Temozolomide—skin cancer	0.000112	0.000654	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—skin cancer	0.000109	0.000636	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000109	0.000632	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—skin cancer	0.000108	0.000628	CcSEcCtD
Erlotinib—Nausea—Temozolomide—skin cancer	0.000107	0.00062	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—skin cancer	0.000106	0.000619	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—skin cancer	0.000105	0.000612	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—skin cancer	0.000105	0.000611	CcSEcCtD
Erlotinib—Rash—Fluorouracil—skin cancer	0.000104	0.000606	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—skin cancer	0.000104	0.000606	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—skin cancer	0.000104	0.000603	CcSEcCtD
Erlotinib—Headache—Fluorouracil—skin cancer	0.000104	0.000603	CcSEcCtD
Erlotinib—ABCB1—head—skin cancer	0.000103	0.0016	CbGeAlD
Erlotinib—Gastrointestinal disorder—Docetaxel—skin cancer	0.000103	0.000599	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—skin cancer	0.000103	0.000598	CcSEcCtD
Erlotinib—Constipation—Docetaxel—skin cancer	0.000102	0.000594	CcSEcCtD
Erlotinib—Pain—Docetaxel—skin cancer	0.000102	0.000594	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—skin cancer	9.81e-05	0.000571	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—skin cancer	9.75e-05	0.000568	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—skin cancer	9.43e-05	0.000549	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—skin cancer	9.43e-05	0.000549	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—skin cancer	8.56e-05	0.000498	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—skin cancer	8.44e-05	0.000491	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—skin cancer	8.16e-05	0.000475	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—skin cancer	7.89e-05	0.000459	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—skin cancer	7.58e-05	0.000441	CcSEcCtD
Erlotinib—Rash—Docetaxel—skin cancer	7.52e-05	0.000438	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—skin cancer	7.51e-05	0.000437	CcSEcCtD
Erlotinib—Headache—Docetaxel—skin cancer	7.47e-05	0.000435	CcSEcCtD
Erlotinib—ABCB1—lymph node—skin cancer	7.23e-05	0.00112	CbGeAlD
Erlotinib—Nausea—Docetaxel—skin cancer	7.08e-05	0.000412	CcSEcCtD
Erlotinib—EGFR—Downstream signal transduction—KRAS—skin cancer	2.54e-05	0.000509	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CDK4—skin cancer	2.53e-05	0.000508	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—NRAS—skin cancer	2.53e-05	0.000508	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KRAS—skin cancer	2.52e-05	0.000507	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	2.52e-05	0.000507	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—skin cancer	2.52e-05	0.000506	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KRAS—skin cancer	2.51e-05	0.000504	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.51e-05	0.000504	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KRAS—skin cancer	2.5e-05	0.000502	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SHH—skin cancer	2.5e-05	0.000501	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	2.46e-05	0.000495	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—HRAS—skin cancer	2.46e-05	0.000494	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—KRAS—skin cancer	2.45e-05	0.000492	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TERT—skin cancer	2.43e-05	0.000489	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—IL6—skin cancer	2.43e-05	0.000488	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL6—skin cancer	2.43e-05	0.000487	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CSPG4—skin cancer	2.42e-05	0.000487	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	2.42e-05	0.000486	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—HRAS—skin cancer	2.4e-05	0.000481	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—skin cancer	2.37e-05	0.000477	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SMO—skin cancer	2.37e-05	0.000475	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTCH1—skin cancer	2.37e-05	0.000475	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.37e-05	0.000475	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—IL6—skin cancer	2.35e-05	0.000472	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KRAS—skin cancer	2.35e-05	0.000472	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KRAS—skin cancer	2.35e-05	0.000472	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	2.35e-05	0.000472	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.34e-05	0.00047	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	2.33e-05	0.000469	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KRAS—skin cancer	2.33e-05	0.000468	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—KRAS—skin cancer	2.32e-05	0.000466	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KRAS—skin cancer	2.31e-05	0.000464	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTGER4—skin cancer	2.3e-05	0.000463	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.3e-05	0.000462	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KRAS—skin cancer	2.3e-05	0.000462	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—IL6—skin cancer	2.29e-05	0.000461	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—HRAS—skin cancer	2.29e-05	0.000461	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—HRAS—skin cancer	2.26e-05	0.000453	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FOXO4—skin cancer	2.24e-05	0.00045	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—skin cancer	2.22e-05	0.000447	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.21e-05	0.000444	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—IL6—skin cancer	2.2e-05	0.000441	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—skin cancer	2.18e-05	0.000438	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FOXO4—skin cancer	2.18e-05	0.000437	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KRAS—skin cancer	2.18e-05	0.000437	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GLI2—skin cancer	2.17e-05	0.000436	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CDK4—skin cancer	2.16e-05	0.000434	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—IL6—skin cancer	2.16e-05	0.000434	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—HRAS—skin cancer	2.16e-05	0.000433	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PLIN2—skin cancer	2.15e-05	0.000432	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.15e-05	0.000431	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—HRAS—skin cancer	2.15e-05	0.000431	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—HRAS—skin cancer	2.13e-05	0.000429	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—HRAS—skin cancer	2.12e-05	0.000427	CbGpPWpGaD
Erlotinib—EGFR—Disease—SHH—skin cancer	2.11e-05	0.000423	CbGpPWpGaD
Erlotinib—EGFR—Disease—ENO2—skin cancer	2.11e-05	0.000423	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	2.09e-05	0.00042	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	2.08e-05	0.000418	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MC1R—skin cancer	2.07e-05	0.000416	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—skin cancer	2.06e-05	0.000414	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—skin cancer	2.06e-05	0.000414	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—skin cancer	2.05e-05	0.000412	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—skin cancer	2.04e-05	0.00041	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GLI1—skin cancer	2.04e-05	0.00041	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLIN2—skin cancer	2.03e-05	0.000409	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—skin cancer	2.03e-05	0.000408	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.01e-05	0.000404	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	2e-05	0.000401	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—HRAS—skin cancer	2e-05	0.000401	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	2e-05	0.000401	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—HRAS—skin cancer	1.98e-05	0.000398	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—HRAS—skin cancer	1.97e-05	0.000396	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—NRAS—skin cancer	1.97e-05	0.000396	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.97e-05	0.000395	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	1.96e-05	0.000394	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—HRAS—skin cancer	1.95e-05	0.000393	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ENO2—skin cancer	1.94e-05	0.00039	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SUFU—skin cancer	1.93e-05	0.000388	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—BRAF—skin cancer	1.93e-05	0.000387	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—skin cancer	1.93e-05	0.000387	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—skin cancer	1.91e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—skin cancer	1.91e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.91e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—skin cancer	1.9e-05	0.000381	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—HRAS—skin cancer	1.89e-05	0.000379	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	1.88e-05	0.000377	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—skin cancer	1.87e-05	0.000376	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLIN2—skin cancer	1.87e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NRAS—skin cancer	1.86e-05	0.000374	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FOXO4—skin cancer	1.86e-05	0.000374	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLIN2—skin cancer	1.85e-05	0.000372	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—skin cancer	1.85e-05	0.000371	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TERT—skin cancer	1.84e-05	0.000369	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—skin cancer	1.81e-05	0.000364	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.77e-05	0.000356	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CSPG4—skin cancer	1.74e-05	0.000349	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NRAS—skin cancer	1.73e-05	0.000348	CbGpPWpGaD
Erlotinib—EGFR—Disease—FOXO4—skin cancer	1.72e-05	0.000345	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.71e-05	0.000344	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—KRAS—skin cancer	1.7e-05	0.000341	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.69e-05	0.00034	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—skin cancer	1.68e-05	0.000338	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.67e-05	0.000335	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—skin cancer	1.65e-05	0.000331	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CSPG4—skin cancer	1.64e-05	0.000329	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.64e-05	0.000329	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLIN2—skin cancer	1.62e-05	0.000326	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KRAS—skin cancer	1.6e-05	0.000322	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—skin cancer	1.55e-05	0.000311	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLIN2—skin cancer	1.53e-05	0.000308	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CSPG4—skin cancer	1.5e-05	0.000302	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TERT—skin cancer	1.5e-05	0.000301	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CSPG4—skin cancer	1.49e-05	0.0003	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KRAS—skin cancer	1.49e-05	0.000299	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SHH—skin cancer	1.47e-05	0.000296	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RASA1—skin cancer	1.47e-05	0.000294	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—BRAF—skin cancer	1.45e-05	0.000292	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—KRAS—skin cancer	1.45e-05	0.000291	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—skin cancer	1.44e-05	0.00029	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.42e-05	0.000284	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—skin cancer	1.41e-05	0.000284	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—skin cancer	1.41e-05	0.000282	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTCH1—skin cancer	1.4e-05	0.000281	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMO—skin cancer	1.4e-05	0.000281	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—skin cancer	1.38e-05	0.000277	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—skin cancer	1.38e-05	0.000277	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—skin cancer	1.36e-05	0.000273	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTGER4—skin cancer	1.36e-05	0.000273	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—KRAS—skin cancer	1.33e-05	0.000267	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CSPG4—skin cancer	1.31e-05	0.000263	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—skin cancer	1.3e-05	0.000262	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLIN2—skin cancer	1.3e-05	0.000261	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—skin cancer	1.27e-05	0.000254	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—skin cancer	1.24e-05	0.000249	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CSPG4—skin cancer	1.23e-05	0.000248	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—skin cancer	1.23e-05	0.000247	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERCC2—skin cancer	1.22e-05	0.000246	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KRAS—skin cancer	1.22e-05	0.000244	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—skin cancer	1.21e-05	0.000243	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—skin cancer	1.21e-05	0.000243	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—KRAS—skin cancer	1.21e-05	0.000243	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FOXO4—skin cancer	1.2e-05	0.000241	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—skin cancer	1.2e-05	0.000241	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—skin cancer	1.19e-05	0.000238	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BRAF—skin cancer	1.19e-05	0.000238	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—skin cancer	1.18e-05	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—skin cancer	1.18e-05	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Disease—TERT—skin cancer	1.15e-05	0.00023	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—skin cancer	1.13e-05	0.000227	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ERCC2—skin cancer	1.13e-05	0.000226	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.12e-05	0.000224	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—skin cancer	1.11e-05	0.000224	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—skin cancer	1.08e-05	0.000218	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—skin cancer	1.07e-05	0.000215	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—skin cancer	1.06e-05	0.000213	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—skin cancer	1.06e-05	0.000212	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ERCC2—skin cancer	1.05e-05	0.000211	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CSPG4—skin cancer	1.05e-05	0.00021	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—skin cancer	1.04e-05	0.000209	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—skin cancer	1.03e-05	0.000208	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—skin cancer	1.03e-05	0.000208	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—skin cancer	1.03e-05	0.000207	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—skin cancer	1.02e-05	0.000205	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—skin cancer	1.02e-05	0.000205	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—skin cancer	1.02e-05	0.000204	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—skin cancer	1.01e-05	0.000203	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLIN2—skin cancer	1e-05	0.000201	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	9.92e-06	0.000199	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—skin cancer	9.9e-06	0.000199	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—skin cancer	9.85e-06	0.000198	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ERCC2—skin cancer	9.57e-06	0.000192	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—skin cancer	9.27e-06	0.000186	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—skin cancer	9.14e-06	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—skin cancer	9.14e-06	0.000183	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—skin cancer	9.09e-06	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—skin cancer	9.08e-06	0.000182	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—skin cancer	8.9e-06	0.000179	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—skin cancer	8.86e-06	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—skin cancer	8.79e-06	0.000177	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—skin cancer	8.77e-06	0.000176	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.72e-06	0.000175	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—skin cancer	8.7e-06	0.000175	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—skin cancer	8.48e-06	0.00017	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—skin cancer	8.42e-06	0.000169	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—skin cancer	8.39e-06	0.000169	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CSPG4—skin cancer	8.07e-06	0.000162	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—skin cancer	8.03e-06	0.000161	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.99e-06	0.000161	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.95e-06	0.00016	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—skin cancer	7.86e-06	0.000158	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—skin cancer	7.77e-06	0.000156	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—skin cancer	7.46e-06	0.00015	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—skin cancer	7.45e-06	0.00015	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—skin cancer	7.43e-06	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—skin cancer	7.34e-06	0.000147	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—skin cancer	7.23e-06	0.000145	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—skin cancer	7.11e-06	0.000143	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—skin cancer	6.99e-06	0.00014	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ERCC2—skin cancer	6.85e-06	0.000138	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—skin cancer	6.79e-06	0.000136	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—skin cancer	6.77e-06	0.000136	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—skin cancer	6.76e-06	0.000136	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—skin cancer	6.68e-06	0.000134	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ERCC2—skin cancer	6.47e-06	0.00013	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—skin cancer	6.41e-06	0.000129	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—skin cancer	6.4e-06	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—skin cancer	6.36e-06	0.000128	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—skin cancer	6.3e-06	0.000127	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—skin cancer	6.23e-06	0.000125	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—skin cancer	6.18e-06	0.000124	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ERCC2—skin cancer	5.94e-06	0.000119	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—skin cancer	5.9e-06	0.000119	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—skin cancer	5.85e-06	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—skin cancer	5.82e-06	0.000117	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—skin cancer	5.74e-06	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—skin cancer	5.71e-06	0.000115	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—skin cancer	5.7e-06	0.000114	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.56e-06	0.000112	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—skin cancer	5.49e-06	0.00011	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—skin cancer	5.45e-06	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—skin cancer	5.32e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—skin cancer	5.29e-06	0.000106	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—skin cancer	5.22e-06	0.000105	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—skin cancer	5.2e-06	0.000104	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—skin cancer	5.17e-06	0.000104	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—skin cancer	5.07e-06	0.000102	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—skin cancer	4.97e-06	9.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—skin cancer	4.95e-06	9.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—skin cancer	4.91e-06	9.87e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—skin cancer	4.87e-06	9.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—skin cancer	4.74e-06	9.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—skin cancer	4.52e-06	9.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—skin cancer	4.33e-06	8.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—skin cancer	4.18e-06	8.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—skin cancer	4.13e-06	8.29e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—skin cancer	4.11e-06	8.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—skin cancer	4e-06	8.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—skin cancer	4e-06	8.03e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—skin cancer	3.88e-06	7.8e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—skin cancer	3.56e-06	7.15e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—skin cancer	3.54e-06	7.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—skin cancer	3.44e-06	6.91e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—skin cancer	3.19e-06	6.4e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—skin cancer	3.1e-06	6.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—skin cancer	3.06e-06	6.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—skin cancer	2.92e-06	5.87e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—skin cancer	2.92e-06	5.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—skin cancer	2.8e-06	5.62e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—skin cancer	2.48e-06	4.97e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—skin cancer	1.91e-06	3.84e-05	CbGpPWpGaD
